ChemicalBook > CAS DataBase List > GZD 824

GZD 824

Product Name
GZD 824
CAS No.
1257628-77-5
Chemical Name
GZD 824
Synonyms
GZD824;GZD8824;GZD-824;GZD 824;GZD-824 Free;Olverembatinib;GZD 824 USP/EP/BP;GZD824;GZD-824;GZD 824;Olverembatinib (GZD824);GZD-824; GZD 824;BENZAMIDE
CBNumber
CB82666626
Molecular Formula
C29H27F3N6O
Formula Weight
532.56
MOL File
1257628-77-5.mol
More
Less

GZD 824 Property

Boiling point:
630.4±55.0 °C(Predicted)
Density 
1.39±0.1 g/cm3(Predicted)
storage temp. 
Store at -20°C
solubility 
DMSO : ≥ 100 mg/mL (187.77 mM)
form 
A crystalline solid
pka
9.04±0.40(Predicted)
color 
Off-white to yellow
More
Less

Hazard and Precautionary Statements (GHS)

More
Less

N-Bromosuccinimide Price

Cayman Chemical
Product number
21508
Product name
GZD-824
Purity
≥98%
Packaging
1mg
Price
$32
Updated
2024/03/01
Cayman Chemical
Product number
21508
Product name
GZD-824
Purity
≥98%
Packaging
5mg
Price
$139
Updated
2024/03/01
Cayman Chemical
Product number
21508
Product name
GZD-824
Purity
≥98%
Packaging
10mg
Price
$243
Updated
2024/03/01
Cayman Chemical
Product number
21508
Product name
GZD-824
Purity
≥98%
Packaging
25mg
Price
$456
Updated
2024/03/01
TRC
Product number
G932028
Product name
GZD824
Packaging
10mg
Price
$195
Updated
2021/12/16
More
Less

GZD 824 Chemical Properties,Usage,Production

Description

GZD-824 is an orally available inhibitor of a broad spectrum of Bcr/Abl tyrosine kinase mutants including T315I (IC50s = 0.34 and 0.68 nM for wild-type Bcr/Abl and Bcr/AblT315I, respectively). It has been shown to suppress the proliferation of Bcr/Abl-positive K562 and Ku812 human chronic myelogenous leukemia cells (IC50s = 0.2 and 0.13 nM, respectively) and induce tumor regression in mouse xenograft tumor models driven by either wild-type or mutant Bcr/Abl.

Uses

GZD824 is a orally bioavailable inhibitor that targets phosphorylated and non-phosphorylated Breakpoint Cluster Region-Abelson (Bcr-Abl) kinases. It is a COVID19-related research product.

Definition

GZD 824 (Olverembatinib), another third-generation BCR-ABL tyrosine kinase inhibitor (TKI), was approved in 2021 in China for patients with T315I positive chronic phase chronic myeloid leukemia (CML-CP) or accelerated-phase CML (CML-AP). Like ponatinib, olverembatinib inhibits multikinases, including B-RAF, DDR1, FGFR, Flt3, KIT, PDGFRα/β, RET, and SRC.

General Description

Class: non-receptor tyrosine kinase
Treatment: CML
Elimination half-life = 17.5–36.5 h

target

BCR-ABL

GZD 824 Preparation Products And Raw materials

Raw materials

Preparation Products

More
Less

GZD 824 Suppliers

China 84 France 1 India 1 United Kingdom 1 United States 10 Global 97
Alsachim SAS
Tel
--
Fax
--
Email
sales@alsachim.com
Country
France
ProdList
424
Advantage
0

1257628-77-5, GZD 824Related Search:

NS-398 ACTIN FROM RABBIT MUSCLE Nilotinib hydrochloride anhydrous Axitinib Cabozantinib Palbociclib Trametinib Dacomitinib (PF299804) Lenvatinib Tofacitinib

  • GZD-824; GZD 824;BENZAMIDE
  • 4-Methyl-N-[4-[(4-methyl-1-piperazinyl)methyl]-3-(trifluoromethyl)phenyl]-3-[2-(1H-pyrazolo[3,4-b]pyridin-5-yl)ethynyl]benzamide
  • 3-(2-(1H-pyrazolo[3,4-b]pyridin-5-yl)ethynyl)-4-methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide
  • GZD8824
  • GZD824;GZD-824;GZD 824
  • GZD-824 Free
  • GZD 824
  • GZD824
  • GZD-824
  • Benzamide, 4-methyl-N-[4-[(4-methyl-1-piperazinyl)methyl]-3-(trifluoromethyl)phenyl]-3-[2-(1H-pyrazolo[3,4-b]pyridin-5-yl)ethynyl]-
  • GZD 824 USP/EP/BP
  • 3-((1H-pyrazolo[3,4-b]pyridin-5-yl)ethynyl)-4-methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide
  • Olverembatinib
  • Olverembatinib (GZD824)
  • 3-[(1H-Pyrazolo[3,4-b]pyridin-5-yl)ethynyl]-4-methyl-N-[4-[(4-methyl-1-piperazinyl)methyl]-3-(trifluoromethyl)phenyl]benzamide
  • 4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}-3-(2-{1H-pyrazolo[3,4-b]pyridin-5-yl}ethynyl)benzamide
  • 1257628-77-5
  • 257628-77-5
  • Inhibitors